Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for vTv Therapeutics (VTVT) over the last 10 years, with Q4 2024 value amounting to $18.7 million.

  • vTv Therapeutics' Current Deferred Revenue fell 9.1% to $18.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.7 million, marking a year-over-year decrease of 9.1%. This contributed to the annual value of $18.7 million for FY2024, which is 9.1% down from last year.
  • According to the latest figures from Q4 2024, vTv Therapeutics' Current Deferred Revenue is $18.7 million, which was down 9.1% from $17000.0 recorded in Q3 2024.
  • Over the past 5 years, vTv Therapeutics' Current Deferred Revenue peaked at $18.7 million during Q2 2022, and registered a low of $17000.0 during Q4 2022.
  • Over the past 5 years, vTv Therapeutics' median Current Deferred Revenue value was $35000.0 (recorded in 2021), while the average stood at $6.6 million.
  • Per our database at Business Quant, vTv Therapeutics' Current Deferred Revenue soared by 10981764.71% in 2023 and then tumbled by 9990.9% in 2024.
  • Quarter analysis of 5 years shows vTv Therapeutics' Current Deferred Revenue stood at $31000.0 in 2020, then grew by 12.9% to $35000.0 in 2021, then crashed by 51.43% to $17000.0 in 2022, then surged by 109817.65% to $18.7 million in 2023, then decreased by 0.09% to $18.7 million in 2024.
  • Its Current Deferred Revenue was $18.7 million in Q4 2024, compared to $17000.0 in Q3 2024 and $17000.0 in Q2 2024.